Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches

  title={Discovery of small molecule inhibitors of ubiquitin-like poxvirus proteinase I7L using homology modeling and covalent docking approaches},
  author={Vsevolod Katritch and Chelsea M. Byrd and Vladimir Tseitin and Dongcheng Dai and Eugene Raush and Maxim Totrov and Ruben Abagyan and Robert Jordan and Dennis E. Hruby},
  journal={Journal of Computer-Aided Molecular Design},
  pages={549 - 558}
Essential for viral replication and highly conserved among poxviridae, the vaccinia virus I7L ubiquitin-like proteinase (ULP) is an attractive target for development of smallpox antiviral drugs. At the same time, the I7L proteinase exemplifies several interesting challenges from the rational drug design perspective. In the absence of a published I7L X-ray structure, we have built a detailed 3D model of the I7L ligand binding site (S2–S2′ pocket) based on exceptionally high structural… 
Activity, Specificity, and Probe Design for the Smallpox Virus Protease K7L*
This first characterization of a poxvirus processing protease demonstrates the importance of dimerization and extended substrate recognition in the control of activity and specificity and provides proof-of-concept for the design of inhibitors and probes that may contribute both to a better understanding of the role of K7L in the virus life cycle and thedesign of novel anti-virals.
Assignment of pterin deaminase activity to an enzyme of unknown function guided by homology modeling and docking.
Of the over 22 million protein sequences in the nonredundant TrEMBL database, fewer than 1% have experimentally confirmed functions. Structure-based methods have been used to predict enzyme
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells.
This modified version of the Fitted docking program, Fitted, implemented in the computational platform, Forecaster, has been modified to carry out automated virtual screening of covalent inhibitors of prolyl oligopeptidase activity, and led to the identification of potential covalents reversible inhibitors of prospecific inhibitory activities.
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
One of the lead-like boronic acid derivatives identified as a covalent immunoproteasome inhibitor is a suitable starting point for chemical optimization and validate the computational protocol that allows the screening of large compound collections.
Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.
Arylsulfonyl fluoride 2 was elaborated to 12, which to the authors' knowledge is the first covalent eIF4E inhibitor with cellular activity and may offer a general strategy for developing selective, lysine-targeted covalENT ligands.
Virtual screening using covalent docking to find activators for G245S mutant p53
In silico screening for potential activators of G245S-mp53, the screening procedure has identified compounds, mostly thiosemicarbazones and halo-carbonyls, with the best potential as G245 smp53 activators, which are described in this work.
Comparative Evaluation of Covalent Docking Tools
It was found that noncovalent docking into Cys/Ala mutated proteins by ICM-Pro and Glide reproduced experimental binding modes with only slightly lower performance and at a significantly lower computational expense than covalents docking did.
Theory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
This review is the first account that highlights different aspects of covalent docking with its merits and pitfalls, and believes that the method and applications highlighted in this study will help future efforts towards the design of irreversible inhibitors.
In Silico Structure-Based Prediction of Receptor–Ligand Binding Affinity: Current Progress and Challenges
The dependence of binding affinity on pH, estimation of entropy along with enthalpy in binding affinity, inclusion of conformational entropy of ligand and receptor, and modulation of flexibilities during complex formation are important challenges lying ahead.


New Class of Orthopoxvirus Antiviral Drugs That Block Viral Maturation
A homology-based bioinformatics approach developed a structural model of the vaccinia virus I7L proteinase, indicating that this is the only gene necessary for resistance, and has potential for development as an efficient antiviral drug against pathogenic orthopoxviruses, including smallpox.
Molecular modeling in cysteine protease inhibitor design.
  • M. Lindvall
  • Biology, Chemistry
    Current pharmaceutical design
  • 2002
This review focuses on examples that use structure-based design or reflect cysteine proteases as a target class and discusses some of the key challenges in developing new tools to evaluate these properties and help in making informed decisions about new templates and leads.
Development of an in vitro cleavage assay system to examine vaccinia virus I7L cysteine proteinase activity
Through the use of transient expression assays and directed genetics, the vaccinia virus (VV) I7L gene product has been implicated as the major maturational proteinase required for viral core protein
Antiviral drug discovery targeting to viral proteases.
The success of anti-HIV-1 therapy using specific and potent protease inhibitors suggests that viral proteases can be the valid molecular targets for the development of antiviral drugs against other viruses.
Targeting HIV protease: from peptidomimetics to non-peptide inhibitors.
  • F. Gago
  • Biology
    IDrugs : the investigational drugs journal
  • 1999
This review covers the development of some of the HIV-1 protease inhibitors, the reasons for this limited success, current therapeutic problems and challenges remaining ahead.
Thiol-dependent enzymes and their inhibitors: a review.
An up-to-date review of the literature on thiol-dependent enzymes as potential targets and their inhibitors designed from peptidic, modified peptidomimetic scaffolds and from small heterocyclic molecules is presented.
Recent developments in structure-based drug design
  • G. Klebe
  • Biology, Chemistry
    Journal of Molecular Medicine
  • 2000
Recent advances in lead discovery via computer screening, iterative design, and understanding of selectivity discrimination are described.
Thiol proteases: inhibitors and potential therapeutic targets.
This review emphasises on the new development from the literature reports since the year 2000 in the exploration of potential cysteine proteases as prospective drug targets, and the investigation of promising inhibitors that can potentially be developed for the treatment of human diseases.
Protease inhibitors in the clinic.
The progress of protease inhibitors into man is assessed, the futures of these enzymes are predicted, and some of the hurdles that have been overcome and that still remain for this promising class of new therapeutic agents are outlined.
African Swine Fever Virus Protease, a New Viral Member of the SUMO-1-specific Protease Family*
The identification of the ASFV protease will allow a better understanding of the role of polyprotein processing in virus assembly and may contribute to the knowledge of the emerging family of SUMO-1-specific proteases.